<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01566019</url>
  </required_header>
  <id_info>
    <org_study_id>2011-A00841-40</org_study_id>
    <secondary_id>2011/1755</secondary_id>
    <nct_id>NCT01566019</nct_id>
  </id_info>
  <brief_title>Molecular Screening for Cancer Treatment Optimization</brief_title>
  <acronym>MOSCATO 02</acronym>
  <official_title>Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to use high throughput molecular analysis (CGH Array
      and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order
      to improve the progression free survival compared to the previous treatment line.

      The secondary objectives are to investigate clinical practical feasibility of such technics,
      to potentially improve the overall survival of patients and to describe molecular portrait of
      Phase 1 candidates.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2011</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) using a targeted treatment selected by molecular profiling compared to the PFS for the most recent regimen</measure>
    <time_frame>From date of start of targeted treatment oriented by MOSCATO until the date of first progression or date of death from any cause, whichever came first, assessed up to 1 year</time_frame>
    <description>Progression according to RECIST criteria or clinical progression or death of any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patient who received a targeted treatment oriented by molecular profiling</measure>
    <time_frame>From the start to the end of enrollment, up to 3 years</time_frame>
    <description>Number of patient who received a targeted treatment oriented by molecular profiling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free Survival, Overall Survival and Response Rate</measure>
    <time_frame>Until progression, up to 1 year</time_frame>
    <description>Comparison of Progression Free Survival, Overall Survival and Response Rate between patients with targeted treatment and others enrolled patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2150</enrollment>
  <condition>Metastatic Solid Tumors (Any Localization)</condition>
  <arm_group>
    <arm_group_label>Patients with non curable metastatic cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumoral biopsy</intervention_name>
    <description>Every enrolled patient undergoes tumoral biopsy</description>
    <arm_group_label>Patients with non curable metastatic cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Solid tumors ; Stade IV ; Local relapse or metastatic ; Uncurable

          -  Age &gt; 6 months

          -  PS 0/1 or Lansky play scale &gt;= 70%

          -  Minimum one treatment line, no limit in the prior number of treatment line

          -  Evaluable or measurable disease

        Exclusion Criteria:

          -  Life expectancy &lt; 3 months

          -  Carcinomatous meningitis

          -  Symptomatic or progressive radiologic brain metastasis for non-CNS tumors

          -  Polynuclear neutrophil &lt; 1 x 10^9/L

          -  Platelets &lt; 100 x 10^9/L

          -  Hemoglobin &lt; 90 g/L

          -  ALT/AST &gt; 2.5 N

          -  bilirubin &gt; 1.5 N

          -  Creatinine &gt;1.5 N

          -  Calcemia &gt; ULN

          -  Phosphate &gt; ULN

          -  Coagulation anomaly non-indicated for biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Charles SORIA, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Charles SORIA, MD, PhD</last_name>
      <phone>+33 1 42 11 42 96</phone>
      <email>soria@igr.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christophe MASSARD, MD</last_name>
      <phone>+33 04 42 11 52 10</phone>
      <email>christophe.massard@igr.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Charles SORIA, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2012</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

